152 related articles for article (PubMed ID: 32579960)
21. L-Tetrahydropalmatine enhances the sensitivity of human ovarian cancer cells to cisplatin via microRNA-93/PTEN/Akt cascade.
Gong J; Xing C; Wang LY; Xie SS; Xiong WD
J BUON; 2019; 24(2):701-708. PubMed ID: 31128026
[TBL] [Abstract][Full Text] [Related]
22. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.
Chan JK; Blansit K; Kiet T; Sherman A; Wong G; Earle C; Bourguignon LY
Gynecol Oncol; 2014 Mar; 132(3):739-44. PubMed ID: 24472409
[TBL] [Abstract][Full Text] [Related]
23. Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972.
Guo J; Pan H
Med Sci Monit; 2019 Dec; 25():9844-9854. PubMed ID: 31865363
[TBL] [Abstract][Full Text] [Related]
24. RUNX1 knockdown induced apoptosis and impaired EMT in high-grade serous ovarian cancer cells.
Chen Y; He Z; Yang S; Chen C; Xiong W; He Y; Liu S
J Transl Med; 2023 Dec; 21(1):886. PubMed ID: 38057816
[TBL] [Abstract][Full Text] [Related]
25. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
26. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
27. MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3.
Wu H; Xiao Z; Zhang H; Wang K; Liu W; Hao Q
Anticancer Drugs; 2014 Aug; 25(7):799-809. PubMed ID: 24686007
[TBL] [Abstract][Full Text] [Related]
28. Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis.
Liu S; Fang Y; Shen H; Xu W; Li H
Acta Biochim Biophys Sin (Shanghai); 2013 Sep; 45(9):756-62. PubMed ID: 23824073
[TBL] [Abstract][Full Text] [Related]
29. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
Chen Y; Cao XY; Li YN; Qiu YY; Li YN; Li W; Wang H
Am J Physiol Cell Physiol; 2018 Aug; 315(2):C225-C235. PubMed ID: 29719173
[TBL] [Abstract][Full Text] [Related]
30. Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells.
Rabelo-Fernández RJ; Santiago-Sánchez GS; Sharma RK; Roche-Lima A; Carrion KC; Rivera RAN; Quiñones-Díaz BI; Rajasekaran S; Siddiqui J; Miles W; Rivera YS; Valiyeva F; Vivas-Mejia PE
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008958
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-155 promotes apoptosis in SKOV3, A2780, and primary cultured ovarian cancer cells.
Chen W; Huang L; Hao C; Zeng W; Luo X; Li X; Zhou L; Jiang S; Chen Z; He Y
Tumour Biol; 2016 Jul; 37(7):9289-99. PubMed ID: 26779627
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA let‑7d‑5p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1.
Chen YN; Ren CC; Yang L; Nai MM; Xu YM; Zhang F; Liu Y
Int J Oncol; 2019 May; 54(5):1771-1784. PubMed ID: 30816441
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
34. Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1.
Li J; Zhi X; Shen X; Chen C; Yuan L; Dong X; Zhu C; Yao L; Chen M
Biochem Biophys Res Commun; 2020 Mar; 523(2):434-440. PubMed ID: 31875843
[TBL] [Abstract][Full Text] [Related]
35. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
[TBL] [Abstract][Full Text] [Related]
36. NCK1-AS1 promotes NCK1 expression to facilitate tumorigenesis and chemo-resistance in ovarian cancer.
Chang H; Li B; Zhang X; Meng X
Biochem Biophys Res Commun; 2020 Feb; 522(2):292-299. PubMed ID: 31761329
[TBL] [Abstract][Full Text] [Related]
37. Decoding molecular interplay between RUNX1 and FOXO3a underlying the pulsatile IGF1R expression during acquirement of chemoresistance.
Dhadve AC; Hari K; Rekhi B; Jolly MK; De A; Ray P
Biochim Biophys Acta Mol Basis Dis; 2020 Jun; 1866(6):165754. PubMed ID: 32142859
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
39. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.
Xia L; Zhang D; Du R; Pan Y; Zhao L; Sun S; Hong L; Liu J; Fan D
Int J Cancer; 2008 Jul; 123(2):372-379. PubMed ID: 18449891
[TBL] [Abstract][Full Text] [Related]
40. PTEN overexpression improves cisplatin-resistance of human ovarian cancer cells through upregulating KRT10 expression.
Wu H; Wang K; Liu W; Hao Q
Biochem Biophys Res Commun; 2014 Feb; 444(2):141-6. PubMed ID: 24434152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
